Skip to content
Bored Studies
RecruitingPhase 1

Drug-Drug Interaction Study of ABP-671 in Gout Patients

Atom Therapeutics Co., Ltd · NCT07367971

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
20
US sites recruiting
1
Study start
January 23, 2026
Record last updated
April 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Being studied: ABP-671 plus allopurinol

Conditions: Gout Chronic; Gout; DDI (Drug-Drug Interaction)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Adults 18-75 years with clinical diagnosis of gout.
  • Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
  • Cohort N: Normal renal function.
  • Cohort R: Moderate renal impairment.

Exclusion Criteria

  • Clinically significant hepatic impairment.
  • History of Allopurinol hypersensitivity.
  • Pregnancy or breastfeeding.

Recruiting US locations

  • Wakefield Clinical Research

    Cary, NC 27560

    Site contact: Xiaohuan Li, MD

Study contacts (from the official record)

  • MaoE Sun · 13914017855 · mao.e.sun@atombp.com
All arthritis studies in North Carolina →
Drug-Drug Interaction Study of ABP-671 in Gout Patients (NCT07367971) | Bored Studies